Business Wire

Biogen Appoints Ginger Gregory Executive Vice President, Chief Human Resources Officer

Jaa

Biogen (NASDAQ: BIIB) announced today the appointment of Ginger Gregory, PhD, as Executive Vice President, Chief Human Resources Officer, effective July 17.

Gregory, who was most recently the Chief Human Resources Officer at Shire Pharmaceuticals, brings more than 20 years of human resources experience to Biogen. She will now lead the company’s global HR function and organizational strategy and will serve as a member of Biogen’s Executive Committee.

“It is exciting to have an HR leader of Ginger’s caliber join us at this time,” said Biogen Chief Executive Officer Michel Vounatsos. “Her extensive experience in our industry makes her especially attuned to the particular organizational and cultural priorities of a company like Biogen. Her expertise will be enormously valuable as we endeavor to attract, develop, and retain a supremely talented, culturally diverse workforce to execute on our mission to transform neuroscience and the treatment of neurological diseases.”

At Shire, Gregory helped lead the integration of several acquired companies, including Baxalta, while consolidating multiple business units into a single organization while overseeing the overhaul of the company’s HR systems globally. Her industry experience also includes HR leadership roles at Bristol-Myers Squibb, Novo Nordisk, and Novartis, working across commercial, R&D and corporate functions. She also served as chief human resources officer at Dunkin’ Brands.

“It is an honor to be entrusted with helping shape the workplace of such a dynamic and well respected industry leader,” said Gregory. “We will remain focused on attracting and cultivating the most talented individuals in our industry as we work to extend our neuroscience leadership and build a culture and operating model that enables individuals and the organization to thrive.”

Dr. Gregory holds an undergraduate degree in psychology from the University of Massachusetts and received her PhD in industrial organizational psychology from George Washington University.

About Biogen
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology, and today the company has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. For more information, please visit www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook, YouTube.

Contact information

Biogen
MEDIA CONTACT:
Jason Glashow, +1-781-464-3260
public.affairs@biogen.com
or
INVESTOR CONTACT:
Matt Calistri, +1-781-464-2442
IR@biogen.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

GSMA Study: 5G to Account for a Third of Europe’s Mobile Market by 202517.10.2017 10:00Tiedote

More than 30 per cent of Europe’s mobile connections will be running on 5G networks by 2025, according to a new GSMA study. The 2017 Europe edition of the GSMA’s Mobile Economy series, published today at the GSMA Mobile 360 Series – Europe event in Brussels, forecasts that there will be 214 million 5G connections in Europe by 2025, establishing the region as one of the largest 5G markets in the world by that point. The first commercial 5G networks in Europe are due to be switched on by 2020 and are expected to provide 5G network coverage to almost three-quarters of Europe’s population by 2025. “Europe has an opportunity to reestablish itself as a global technology leader as we move toward the 5G era, but this can only happen if policymakers move quickly and boldly to make the necessary regulatory reforms to boost the region’s competitiveness on the global stage and bring innovative ser

REFLEX CES Partners with NOLAM EMBEDDED SYTEMS to Provide Integrated CANbus IP Core Solutions on FPGA COTS Boards17.10.2017 10:00Tiedote

NOLAM EMBEDDED SYSTEMS, manufacturer of semiconductor IP and board level products and systems for the Aerospace, Defense, telecom and industrial markets, today announced their partnership with REFLEX CES, a leading provider of complex, high-density FPGA-based boards. This partnership benefits customers by providing them a fully integrated solution based on REFLEX CES FPGA boards and NOLAM EMBEDDED SYSTEMS CANbus IP core and CANbus FMC module. «We are thrilled to collaborate with REFLEX CES to offer a fully integrated CANbus solution», stated Benjamin Nakache, Vice-President of Sales at Nolam Embedded Systems «By integrating our CANbus IP solution with our CANbus FMC to the REFLEX CES hardware, we bring a very easy-to use solution to CANbus users in the automotive industry.» One of the first outcomes of this collaborative venture is the release of an SDK, composed of REF

BNP Paribas Implements SmartStream’s TLM Fees and Expense Management Solution17.10.2017 10:00Tiedote

SmartStream, the Financial Transaction Lifecycle Management (TLM®) specialist, today announced that the Derivatives Execution & Clearing (DEC) business of BNP Paribas CIB has implemented its TLM Fees & Expense Management (FEMS) solution for two key objectives: To control and reconcile payable brokerage fees Invoice issuance to execute commissions for DEC clients FEMS will consolidate all fees which will be reconciled against invoices received. The solution will automate the invoice control process by managing the increase in volume growth and targeting essentially (1) the detection and resolution of disputes and (2) an acceleration of processing and payment turnaround time. Also, the solution will fully support the execution and commission billing process from DEC to its clients. Pierre Duret, Head of Clearing within BNP Pari

East and West Malaysia Gain Enhanced Mobile Broadband with SES Networks and CompuDyne17.10.2017 09:50Tiedote

CompuDyne, a leading telecommunications solutions provider in Malaysia, is partnering with SES Networks to bring high quality and cost-effective cellular backhaul service to both East and West Malaysia and its surrounding islands. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171016006356/en/ East and West Malaysia Gain Enhanced Mobile Broadband with SES Networks and CompuDyne (Photo: Business Wire) SES announced that CompuDyne has signed a multi-year, multi-transponder agreement to lease Ku-band capacity on SES-9, SES’s largest satellite dedicated to serve Asia-Pacific, for its customer Digi, the country’s leading mobile network operator. Making a shift from a C-band to Ku-band system, CompuDyne can now deliver more cost-effective and reliable satellite connectivity, enabling Digi

AstraZeneca and Chi-Med’s Savolitinib Shows Encouraging Clinical Activity in 2nd-Line EGFR Mutation-positive Lung Cancer with MET-amplification17.10.2017 01:00Tiedote

AstraZeneca and its partner Chi-Med today presented preliminary safety and clinical activity of savolitinib when given in combination with either Tagrisso (osimertinib) or Iressa (gefitinib) in two Phase Ib trials conducted in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) with MET-amplification who had progressed following 1st-line treatment with an EGFR inhibitor.1,2 In both trials, the addition of savolitinib (600mg, once daily), an investigational selective inhibitor of c-MET (mesenchymal epithelial transition factor) receptor tyrosine kinase, to osimertinib (80mg, once daily) or gefitinib (250mg, once daily) demonstrated preliminary anti-tumour activity. The data were shared in two oral presentations at the International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan, 15-18 Oc

Orlando Melbourne Int’l (MLB) Lands Largest FAA Grant in Its History17.10.2017 00:34Tiedote

When Air Force One landed at Orlando Melbourne International Airport (MLB) in February, Airport Executive Director Greg Donovan took advantage of the opportunity and advised the president of the United States that his 747-200 just landed on a commercial runway officially rated ‘poor’ in aviation terms. That’s going to change, thanks to an $18,132,588 FAA grant announced by U.S. Secretary of Transportation Elaine Chao today. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171016006292/en/ Greg Donovan, A.A.E. (Photo: Business Wire) “We asked for, and received, tremendous support from the Florida congressional delegation,” said Jack L. Ryals, chairman of the Melbourne Airport Authority. “We are deeply grateful to Congressman Posey, Senator Nelson and Senator Rubio for their advocacy on this critic

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme